Welcome to our dedicated page for Orasure Tech SEC filings (Ticker: OSUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing OraSure Technologies鈥� regulatory paperwork can feel like sifting through lab samples鈥攅ssential details are spread across hundreds of pages and dense FDA terminology. Whether you鈥檙e hunting for diagnostic-segment margins or tracking when executives trade shares, the disclosures are easy to miss. This page gathers every document the moment it hits EDGAR, delivering OraSure Technologies SEC filings explained simply.
Our AI engine reads the filings side-by-side with you, turning a 250-page OraSure Technologies annual report 10-K simplified into a two-minute brief, flagging revenue shifts driven by oral-fluid HIV tests and molecular collection kits. Need the next OraSure Technologies quarterly earnings report 10-Q filing? It appears here with instant OraSure Technologies earnings report filing analysis, plus red-lined changes from prior quarters. AG真人官方-time alerts highlight OraSure Technologies insider trading Form 4 transactions, so you can see OraSure Technologies Form 4 insider transactions real-time without refreshing the page.
Use the menu to jump straight to OraSure Technologies 8-K material events explained, the latest OraSure Technologies proxy statement executive compensation tables, or in-depth notes on FDA clearances embedded in footnotes. Our AI summaries clarify why a supply-chain disclosure matters, and a comparison tool helps professionals understand molecular solutions revenue trends quarter over quarter. Still unsure? A one-click guide for understanding OraSure Technologies SEC documents with AI answers common questions and points you to OraSure Technologies executive stock transactions Form 4 for context. Spend less time reading, more time deciding.
Amendment No. 1 to Schedule 13G reveals that Private Management Group, Inc. (PMG) has accumulated 5,461,440 OraSure Technologies (OSUR) common shares, representing 7.3 % of the outstanding class as of 06/30/2025. PMG, a California-based registered investment adviser ("IA"), reports sole voting and sole dispositive power over the entire position and certifies the holding is a passive investment made in the ordinary course of business under Rule 13d-1(b). Because the stake exceeds the 5 % threshold, PMG is required to file this disclosure; the form contains no proposals to influence control, no group affiliations, and no subsidiary ownership.
- Ownership details: 5.46 M shares; no shared voting/dispositive power.
- Filing classification: Investment Adviser (IA) under 搂240.13d-1(b)(1)(ii)(E).
- Certification: PMG states it is not pursuing control or activist objectives.
- Signatory: Robert T. Summers, CFA, Co-President, signed on 07/25/2025.
The disclosure signals fresh or increased institutional interest but by itself does not alter OraSure鈥檚 governance or strategic direction.
OraSure Technologies, Inc. (OSUR) 鈥� Form 4 insider filing: On 24 June 2025, director John P. Kenny received 6,657 shares of common stock under the company鈥檚 Stock Award Plan in lieu of cash fees. The award vested immediately at a reference price of $3.0082 per share. Following the grant, Kenny鈥檚 direct ownership increased to 147,204 shares. No derivative securities were reported and no shares were sold.
FAQ
What is the current stock price of Orasure Tech (OSUR)?
What is the market cap of Orasure Tech (OSUR)?
What primary products does OraSure Technologies manufacture?
How does the diagnostics segment contribute to the company's business?
What role does molecular testing play in OraSure's product portfolio?
In which markets does OraSure Technologies operate?
How does OraSure ensure the quality of its diagnostic tests?
What competitive advantages does OraSure hold in the diagnostics industry?
What are the key regulatory considerations for OraSure's products?
How does OraSure support various healthcare sectors?
